Nevro Corp (NVRO)

Mar 21, 2025, 11:30 AM EDT - 13 days ago

NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

GMED

Mar 4, 2025, 4:15 PM EST - 4 weeks ago

Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

GMED

Jan 21, 2025, 4:30 PM EST - 2 months ago

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Jan 13, 2025, 8:30 AM EST - 2 months ago

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results

Dec 2, 2024, 2:29 PM EST - 4 months ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

GKOS ISRG SYK

Nov 18, 2024, 8:30 AM EST - 4 months ago

New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches

Nov 12, 2024, 7:00 AM EST - 5 months ago

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

Nov 11, 2024, 9:11 PM EST - 5 months ago

Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 5 months ago

Nevro Reports Third-Quarter 2024 Financial Results

Oct 29, 2024, 4:30 PM EDT - 5 months ago

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Oct 10, 2024, 4:45 PM EDT - 6 months ago

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024

Sep 24, 2024, 8:00 AM EDT - 6 months ago

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation

Aug 28, 2024, 4:15 PM EDT - 7 months ago

Nevro to Present at Wells Fargo 2024 Healthcare Conference

Aug 9, 2024, 3:47 PM EDT - 8 months ago

Nevro: Not Having My Back

Aug 7, 2024, 5:54 AM EDT - 8 months ago

Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 8 months ago

Nevro Reports Second-Quarter 2024 Financial Results

Jul 9, 2024, 4:15 PM EDT - 9 months ago

Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024

Jun 11, 2024, 4:15 PM EDT - 10 months ago

Nevro to Present at Truist Securities MedTech Conference

May 9, 2024, 4:05 PM EDT - 11 months ago

Nevro to Present at BofA Securities 2024 Healthcare Conference

May 8, 2024, 2:01 AM EDT - 11 months ago

Nevro Corp. (NVRO) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 11 months ago

Nevro Reports First-Quarter 2024 Financial Results

Apr 17, 2024, 8:30 AM EDT - 1 year ago

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Feb 28, 2024, 4:10 PM EST - 1 year ago

Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Feb 21, 2024, 11:02 PM EST - 1 year ago

Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 4:06 PM EST - 1 year ago

Nevro Enters Into Cooperation Agreement With Engaged Capital

Feb 21, 2024, 4:05 PM EST - 1 year ago

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

Feb 1, 2024, 4:30 PM EST - 1 year ago

Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

Jan 29, 2024, 4:30 PM EST - 1 year ago

Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024

Jan 18, 2024, 4:15 PM EST - 1 year ago

Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy

Jan 17, 2024, 4:15 PM EST - 1 year ago

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Jan 9, 2024, 8:50 AM EST - 1 year ago

Nevro laying off 63 employees; revenue to beat analyst estimates

Jan 9, 2024, 8:30 AM EST - 1 year ago

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results

Jan 4, 2024, 4:15 PM EST - 1 year ago

Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 30, 2023, 5:19 PM EST - 1 year ago

Nevro Announces Acquisition of Vyrsa™ Technologies

Nov 20, 2023, 7:00 AM EST - 1 year ago

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nov 1, 2023, 4:01 PM EDT - 1 year ago

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

Oct 4, 2023, 7:00 AM EDT - 1 year ago

Nevro to Report Third Quarter 2023 Financial Results

Sep 18, 2023, 7:00 AM EDT - 1 year ago

New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

Sep 1, 2023, 3:54 PM EDT - 1 year ago

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Aug 23, 2023, 7:00 AM EDT - 1 year ago

Nevro Announces Participation in Upcoming Investor Conferences

Aug 16, 2023, 7:00 AM EDT - 1 year ago

New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Aug 1, 2023, 8:11 PM EDT - 1 year ago

Nevro Corp. (NVRO) Q2 2023 Earnings Call Transcript

Aug 1, 2023, 4:03 PM EDT - 1 year ago

Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance

Jul 13, 2023, 7:00 AM EDT - 1 year ago

Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference

Jul 12, 2023, 7:00 AM EDT - 1 year ago

Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jun 27, 2023, 7:00 AM EDT - 1 year ago

Nevro to Report Second Quarter 2023 Financial Results

Jun 23, 2023, 7:00 AM EDT - 1 year ago

Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions